Infection rates in a large investigational trial of sacral nerve stimulation for fecal incontinence.
ABSTRACT Treatment options for patients with fecal incontinence (FI) are limited, and surgical treatments can be associated with high rates of infection and other complications. One treatment, sacral nerve stimulation (SNS), is approved for FI in Europe. A large multicenter trial was conducted in North America and Australia to assess the efficacy of SNS in patients with chronic fecal incontinence. The aim of this report was to analyze the infectious complication rates in that trial.
Adult patients with a history of chronic fecal incontinence were enrolled into this study. Those patients who fulfilled study inclusion/exclusion criteria and demonstrated greater than two FI episodes per week underwent a 2-week test phase of SNS. Patients who showed a > or = 50% reduction in incontinent episodes and/or days per week underwent chronic stimulator implantation. Adverse events were reported to the sponsor by investigators at each study site and then coded. All events coded as implant site infection were included in this analysis.
One hundred twenty subjects (92% female, 60.5 +/- 12.5 years old) received a chronically implanted InterStim Therapy device (Medtronic, Minneapolis, MN, USA). Patients were followed for an average of 28 months (range 2.2-69.5). Thirteen of the 120 implanted subjects (10.8%) reported infection after the chronic system implant. One infection spontaneously resolved and five were successfully treated with antibiotics. Seven infections (5.8%) required surgical intervention, with infections in six patients requiring full permanent device explantation. The duration of the test stimulation implant procedure was similar between the infected group (74 min) and the non-infected group (74 min). The average duration of the chronic neurostimulator implant procedure was also similar between the infected (39 min) and non-infected group (37 min). Nine infections occurred within a month of chronic system implant and the remaining four infections occurred more than a year from implantation. While the majority (7/9) of the early infections was successfully treated with observation, antibiotics, or system replacement, all four of the late infections resulted in permanent system explantation.
SNS for FI resulted in a relatively low infection rate. This finding is especially important because the only other Food and Drug Administration-approved treatment for end-stage FI, the artificial bowel sphincter, reports a much higher rate. Combined with its published high therapeutic success rate, this treatment has a positive risk/benefit profile.
Conference Paper: A multi-module PWM switched-reactor-based static VAr compensator[Show abstract] [Hide abstract]
ABSTRACT: This paper presents a variable reactance-type static VAr compensator (SVC) which employs force-commutated switches as well as thyristors. The proposed compensator employs thyristor switched capacitors (TSC) and a fixed capacitor bank to control, in steps, the amount of reactive power generated. Fine adjustment of the reactive power generated and also the reactive power absorbed by the SVC are obtained with N modules of a new four-switch (force-commutated) PWM controllable reactor. These are controlled with phase shifted carriers in order to achieve harmonic cancellation. The features of this multi-module PWM SVC are analyzed using switching functions and confirmed with simulation resultsPower Electronics Specialists Conference, 1996. PESC '96 Record., 27th Annual IEEE; 07/1996
- [Show abstract] [Hide abstract]
ABSTRACT: Dynamic or flexible regression models are used more and more often in carcinogenesis studies to relate lifetime distribution to time-depending explanatory variables. In addition to the classical regression models, such as the Cox model, AFT model, Linear transformation model, Frailty model, etc., we expose so-called flexible regression models, which are well adapted to study cross-effects of survival functions. Such effects are sometimes observed in clinical trials. Classical examples are well-known data concerning effects of chemotherapy (CH) and chemotherapy plus radiotherapy (CH + R) on survival times of gastric cancers patients. In this paper, we give examples which illustrate possible applications of the Hsieh model (2001) and the SCE model proposed by Bagdonavicius and Nikulin and adapted to treat survival data with one crossing point. We compare both models. Biblipgraphy: 40 titles.Journal of Mathematical Sciences 08/2007; 145(2):4880-4893. DOI:10.1007/s10958-007-0322-z
- [Show abstract] [Hide abstract]
ABSTRACT: Sacral nerve stimulation is offered to patients presenting with fecal incontinence of neurological or idiopathic etiology, when medical management has failed. The purpose of this study was to investigate the causes of surgical revision following sacral nerve stimulation in consecutive patients who had received implants. From September 2001 to August 2009, 123 patients (105 women) of mean age 56 years were operated on for neurological (n = 104) or idiopathic (n = 19) fecal incontinence. The mean preoperative Cleveland Clinic score was 13/20 (range 6/20 to 19/20). Eighty-seven patients of 123 had a positive test and underwent stimulator implantation. Any stimulator dysfunction was prospectively studied. Among the 87 patients, 36 had surgical revision of the device for the following reasons: device-related failure due to infection in 4 (successful reimplant in 4), electrode displacement in 2, electrode breakage in 2 (reimplantation of electrode in 4), and dysfunction owing to impedance increase of the system in 4; adverse stimulation with pain in 7 (stimulator repositioning in 4 and explantation in 3); battery depletion either spontaneously (n = 6) or owing to a MRI examination (n = 2); total or partial loss of clinical efficacy in 9 (removal of the generator and electrode). Sacral nerve stimulation is a recognized treatment for fecal incontinence. The stimulator reoperation rate is high and is caused by stimulator dysfunction in 24% of cases.Diseases of the Colon & Rectum 11/2010; 53(11):1501-7. DOI:10.1007/DCR.0b013e3181f1cf14 · 3.20 Impact Factor